Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)

Clinical trial NCT03703167 · COMPLETED

Trial details

NCT number: NCT03703167
Sponsor: Memorial Sloan Kettering Cancer Center
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Primary Central Nervous System Lymphoma (PCNSL)Secondary Central Nervous System Lymphoma (SCNSL)

Start date: 2019-01-22
Primary completion: 2026-01-26
Enrollment: 25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.